Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2016
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XX52
|
| gptkbp:bioavailability |
~60%
|
| gptkbp:brand |
gptkb:Venclexta
gptkb:Venclyxto |
| gptkbp:CASNumber |
1257044-40-8
|
| gptkbp:chemicalFormula |
C45H50ClN7O7S
|
| gptkbp:developer |
gptkb:AbbVie
gptkb:Genentech |
| gptkbp:eliminationHalfLife |
16-19 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
venetoclax
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
BCL-2 inhibitor
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:molecularWeight |
868.4 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea diarrhea neutropenia thrombocytopenia |
| gptkbp:usedFor |
gptkb:small_lymphocytic_lymphoma
gptkb:acute_myeloid_leukemia chronic lymphocytic leukemia |
| gptkbp:bfsParent |
gptkb:Bcl-2
gptkb:Venclexta gptkb:BCL2 |
| gptkbp:bfsLayer |
7
|